Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefitinib - AstraZeneca

Drug Profile

Gefitinib - AstraZeneca

Alternative Names: Iressa; ZD 1839

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Hutchison MediPharma; Massachusetts General Hospital; MedImmune; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Morpholines; Phenyl ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Salivary gland cancer
  • No development reported Head and neck cancer
  • Discontinued Bladder cancer; Brain metastases; Breast cancer; Colorectal cancer; Glioblastoma; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 26 Sep 2018 AstraZeneca and Massachusetts General Hospital completes a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease) in Singapore (PO) (NCT00809237)
  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top